SEC Form 4 · accession 0001179110-19-001908
MOMENTA PHARMACEUTICALS INC · MNTA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony M. Manning
Officer — Chief Scientific Officer
Period of report
Feb 12, 2019
Accepted (ET)
Feb 14, 2019 · 4:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235010
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF3 | Feb 12, 2019 | M | 25,000 | — | A | 88,167 | D | |
| Common Stock | Feb 13, 2019 | S | 7,717 | $12.70 | D | 80,450 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3,F4 | — | Feb 12, 2019 | M | 25,000 | D | — | — | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1Shares received pursuant to settlement of Restricted Stock Units that were granted on February 12, 2018.
- F2This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- F3Restricted Stock Units convert into common stock on a one-for-one basis.
- F4Subject to the officer's continued employment with the company, the restricted stock units will vest with respect to 50% of the shares on the first anniversary of the grant date, and the remaining 50% will vest on the second anniversary of the grant date.